Longeveron meets with FDA on heart syndrome drug trial

May 8, 2026 4:05 PM

Longeveron Inc. (NASDAQ: LGVN) held a Type C meeting with the U.S. Food and Drug Administration in late March regarding ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found